Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177003 | 0.88 | ALDH1A1 (0.51) | ATAD2ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL588343 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDMEN1XBP1 | |
| SCHEMBL67540 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDMEN1XBP1 | |
| SCHEMBL111187 | 0.77 | CA12 (0.58) | ATAD2ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL654773 | 0.77 | CA1 (0.58) | ATAD2ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL630490 | 0.76 | NOTUM (0.66) | ATAD2ALDH1A1MAPTHPGDNOTUM | |
| SCHEMBL31647047 | 0.76 | TP53 (0.40) | ATAD2ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL630815 | 0.76 | NOTUM (0.66) | ALDH1A1MAPTHPGDMEN1XBP1 | |
| Hydrochloric Acid SCHEMBL111186 | 0.75 | CA12 (0.56) | ATAD2ALDH1A1MAPTHPGDKDM4E | |
| Hydrochloric Acid SCHEMBL9494959 | 0.75 | CA1 (0.56) | ATAD2ALDH1A1MAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8796485-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2554165-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| EP-2551262-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | Ajinomoto Co., Inc. (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20110251418-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | CASR, GIPR, GRPR | ATAD2 1784/4885ALDH1A1 2603/4885MAPT 2352/4885 |
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | ATAD2 2203/4885ALDH1A1 2705/4885MAPT 3790/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | ATAD2 1934/4885ALDH1A1 2335/4885MAPT 4605/4885 |
| US-20110251418-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | ATAD2 2203/4885ALDH1A1 2705/4885MAPT 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.